GATC Biotech has expanded its liquid biopsy service with GATCLIQUID ONCOTARGET. A simple blood draw enables sensitive detection of blood cancers, such as acute myeloid leukemia and myeloproliferative neoplasms, in addition to melanoma, lung, colorectal, and pancreatic cancers, through analysis of actionable mutations in circulating tumor DNA. The service profiles 12 cancer genomic alterations so far. The continuously expanding target list makes GATCLIQUID ONCOTARGET suitable for detection and regular monitoring of various cancers that are difficult to characterize with conventional diagnostic procedures. Clinical researchers can explore, screen, and monitor a wide range of tumor-related mutations for close surveillance of tumor dynamics and cancer heterogeneity in individual patients. This droplet-digital PCR test detects genomic alterations with a sensitivity as low as 0.1%. Proprietary workflows and cutting-edge technologies enable quantification of low-level mutations during treatment as well as detection of cancer recurrence, often prior to clinical progression.